115 related articles for article (PubMed ID: 8695267)
1. Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas.
Stragliotto G; Vega F; Stasiecki P; Gropp P; Poisson M; Delattre JY
Eur J Cancer; 1996 Apr; 32A(4):636-40. PubMed ID: 8695267
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas.
Faillot T; Magdelénat H; Mady E; Stasiecki P; Fohanno D; Gropp P; Poisson M; Delattre JY
Neurosurgery; 1996 Sep; 39(3):478-83. PubMed ID: 8875477
[TBL] [Abstract][Full Text] [Related]
3. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.
Ramos TC; Figueredo J; Catala M; González S; Selva JC; Cruz TM; Toledo C; Silva S; Pestano Y; Ramos M; Leonard I; Torres O; Marinello P; Pérez R; Lage A
Cancer Biol Ther; 2006 Apr; 5(4):375-9. PubMed ID: 16575203
[TBL] [Abstract][Full Text] [Related]
4. A new treatment for high grade gliomas of the brain.
Brady LW
Bull Mem Acad R Med Belg; 1998; 153(5-6):255-61; discussion 261-2. PubMed ID: 9988932
[TBL] [Abstract][Full Text] [Related]
5. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
[TBL] [Abstract][Full Text] [Related]
6. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A.
Gruber R; van Haarlem LJ; Warnaar SO; Holz E; Riethmüller G
Cancer Res; 2000 Apr; 60(7):1921-6. PubMed ID: 10766181
[TBL] [Abstract][Full Text] [Related]
7. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial.
Brady LW; Miyamoto C; Woo DV; Rackover M; Emrich J; Bender H; Dadparvar S; Steplewski Z; Koprowski H; Black P
Int J Radiat Oncol Biol Phys; 1992; 22(1):225-30. PubMed ID: 1309204
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx.
Bier H; Hoffmann T; Hauser U; Wink M; Ochler M; Kovar A; Müser M; Knecht R
Cancer Chemother Pharmacol; 2001 Jun; 47(6):519-24. PubMed ID: 11459205
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Sipos L; Vitanovics D; Afra D
Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
[TBL] [Abstract][Full Text] [Related]
10. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.
Hayes RL; Koslow M; Hiesiger EM; Hymes KB; Hochster HS; Moore EJ; Pierz DM; Chen DK; Budzilovich GN; Ransohoff J
Cancer; 1995 Sep; 76(5):840-52. PubMed ID: 8625188
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
Chamberlain MC; Kim BT
J Neurooncol; 2017 Jul; 133(3):561-569. PubMed ID: 28500559
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor.
Crombet T; Torres O; Neninger E; Catalá M; Rodríguez N; Ramos M; Fernández E; Iznaga N; Pérez R; Lage A
Cancer Biother Radiopharm; 2001 Feb; 16(1):93-102. PubMed ID: 11279803
[TBL] [Abstract][Full Text] [Related]
13. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
Osenga KL; Hank JA; Albertini MR; Gan J; Sternberg AG; Eickhoff J; Seeger RC; Matthay KK; Reynolds CP; Twist C; Krailo M; Adamson PC; Reisfeld RA; Gillies SD; Sondel PM;
Clin Cancer Res; 2006 Mar; 12(6):1750-9. PubMed ID: 16551859
[TBL] [Abstract][Full Text] [Related]
14. The use of epidermal growth factor receptor-425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of patients with high grade gliomas of the brain.
Miyamoto CT; Brady LW; Rackover MA; Emrich J; Class R; Bender H; Micaily B; Steplewski Z
Recent Results Cancer Res; 1996; 141():183-92. PubMed ID: 8722428
[No Abstract] [Full Text] [Related]
15. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer.
Modjtahedi H; Hickish T; Nicolson M; Moore J; Styles J; Eccles S; Jackson E; Salter J; Sloane J; Spencer L; Priest K; Smith I; Dean C; Gore M
Br J Cancer; 1996 Jan; 73(2):228-35. PubMed ID: 8546911
[TBL] [Abstract][Full Text] [Related]
16. Induction of a T- and B-cell response against a unique amino acid sequence of the mouse IgG2A hinge region in a MAb-treated patient.
Wersäll P; Fagerberg J; Ohlsson I; Rudén U; Boethius J; Mellstedt H
Int J Cancer; 1997 Dec; 73(6):790-4. PubMed ID: 9399653
[TBL] [Abstract][Full Text] [Related]
17. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
18. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.
Bigner DD; Brown MT; Friedman AH; Coleman RE; Akabani G; Friedman HS; Thorstad WL; McLendon RE; Bigner SH; Zhao XG; Pegram CN; Wikstrand CJ; Herndon JE; Vick NA; Paleologos N; Cokgor I; Provenzale JM; Zalutsky MR
J Clin Oncol; 1998 Jun; 16(6):2202-12. PubMed ID: 9626222
[TBL] [Abstract][Full Text] [Related]
19. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid.
Yung WK; Kyritsis AP; Gleason MJ; Levin VA
Clin Cancer Res; 1996 Dec; 2(12):1931-5. PubMed ID: 9816151
[TBL] [Abstract][Full Text] [Related]
20. EGFRvIII as a promising target for antibody-based brain tumor therapy.
Kuan CT; Wikstrand CJ; Bigner DD
Brain Tumor Pathol; 2000; 17(2):71-8. PubMed ID: 11210174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
